ArticleNeuromuscular disorders : NMD2010
Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation.
Article in Neuromuscular disorders : NMD, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 60 citations in OpenAlex.
- Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial.Orphanet journal of rare diseases · 2013Trial
- Designing the MyoFusion Media: A Serum-Free Medium Optimized for Bovine Satellite Cell Differentiation.Biotechnology and bioengineering · 2026Article
- Effects of photobiomodulation on the differentiation, viability, and migration of C2C12 myoblasts exposed to different concentrations of dexamethasone.Scientific reports · 2026Article
- Promoting and accelerating muscle regeneration through cell therapy in a mouse model.Journal of Taibah University Medical Sciences · 2024Article
- Bioengineered Model of Human LGMD2B Skeletal Muscle Reveals Roles of Intracellular Calcium Overload in Contractile and Metabolic Dysfunction in Dysferlinopathy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The dose-response effects of arachidonic acid on primary human skeletal myoblasts and myotubes.Journal of the International Society of Sports Nutrition · 2023Article
- Influence of COPD systemic environment on the myogenic function of muscle precursor cells in vitro.Respiratory research · 2022Article
- Differential Expression of Long Noncoding RNAs in Murine Myoblasts After Short Hairpin RNA-Mediated Dysferlin Silencing In Vitro: Microarray Profiling.JMIR bioinformatics and biotechnology · 2022Article
- Dexamethasone accelerates muscle regeneration by modulating kinesin-1-mediated focal adhesion signals.Cell death discovery · 2021Article
- Detecting the Effects of the Glucocorticoid Dexamethasone on Primary Human Skeletal Muscle Cells-Differences to the Murine Cell Line.International journal of molecular sciences · 2020Article
- Functions of Vertebrate Ferlins.Cells · 2020Review
- Engineered skeletal muscles for disease modeling and drug discovery.Biomaterials · 2019Review
- Dexamethasone-induced impairment of post-injury skeletal muscle regeneration.BMC veterinary research · 2019Article
- Fer1l6 is essential for the development of vertebrate muscle tissue in zebrafish.Molecular biology of the cell · 2019Article
- Effects of Dexamethasone Dose and Timing on Tissue-Engineered Skeletal Muscle Units.Cells, tissues, organs · 2018Article
- Glucocorticoids Improve Myogenic Differentiation In Vitro by Suppressing the Synthesis of Versican, a Transitional Matrix Protein Overexpressed in Dystrophic Skeletal Muscles.International journal of molecular sciences · 2017Article
- Effects of Dexamethasone on Satellite Cells and Tissue Engineered Skeletal Muscle Units.Tissue engineering. Part A · 2016Article
- Growth Factors for Skeletal Muscle Tissue Engineering.Cells, tissues, organs · 2016Review
- Context-dependent effects of feather corticosterone on growth rate and fledging success of wild passerine nestlings in heterogeneous habitat.Oecologia · 2015Article
- Dysferlin regulates cell membrane repair by facilitating injury-triggered acid sphingomyelinase secretion.Cell death & disease · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Glucocorticoids are beneficial in many muscular dystrophies but they are ineffective in treating dysferlinopathy, a rare muscular dystrophy caused by loss of dysferlin. We sought to understand the molecular basis for this disparity by studying the effects of a glucocorticoid on differentiation of the myoblast cell line, C2C12, and dysferlin-deficient C2C12s. We found that pharmacologic doses of dexamethasone enhanced the myogenic fusion efficiency of C2C12s and increased the induction of dysferlin, along with specific myogenic transcription factors, sarcolemmal and structural proteins. In contrast, the dysferlin-deficient C2C12 cell line demonstrated a reduction in long myotubes and early induction of particular muscle differentiation proteins, most notably, myosin heavy chain. Dexamethasone partially reversed the defect in myogenic fusion in the dysferlin-deficient C2C12 cells. We hypothesize that a key therapeutic benefit of glucocorticoids may be the up-regulation of dysferlin as an important component of glucocorticoid-enhanced myogenic differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.